Quarterly ResultJul 30, 2026, 04:53 PM
Guardant Health Q2 Revenue Jumps 44% to $335M; Net Loss $120.1M
AI Summary
Guardant Health reported a significant increase in revenue for the second quarter of 2026, reaching $334.98 million, a 44.3% rise year-over-year. However, the company's net loss also widened to $120.14 million for the quarter. Key business developments include the FDA approval of its Guardant360 Liquid CDx test and the Shield blood test for primary colorectal cancer screening, which also meets Medicare coverage requirements.
Key Highlights
- Q2 2026 revenue increased 44.3% to $334.98 million from $232.09 million in Q2 2025.
- Net loss for Q2 2026 was $120.14 million, up from $99.90 million in Q2 2025.
- Revenue for the six months ended June 30, 2026, was $636.64 million.
- Net loss for the six months ended June 30, 2026, was $232.22 million.
- Guardant360 Liquid CDx test received FDA approval in Q2 2026.
- Shield blood test received FDA approval for primary colorectal cancer screening.
- Oncology revenue for Q2 2026 was $219.11 million, Screening revenue was $52.87 million.
Price Impact
More from GH